Patents by Inventor R. Scott Thies
R. Scott Thies has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10351821Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.Type: GrantFiled: October 16, 2017Date of Patent: July 16, 2019Assignee: Asterias Biotherapeutics Inc.Inventors: Melissa K. Carpenter, R. Scott Thies
-
Publication number: 20190024053Abstract: This invention provides a system for obtaining cells of the chondrocyte lineage by differentiating primate pluripotent stem cells. The process involves culturing the cells as a micromass or other aggregate form in a cocktail of differentiation agents that facilitates outgrowth of the desired cell type. Progeny are capable of synthesizing Type II collagen or aggrecan, or other products that are characteristic of the chondrocyte lineage. Chondrocytes and chondrocyte precursor cells obtained according to this disclosure are suitable for use in both research and clinical therapy.Type: ApplicationFiled: January 22, 2018Publication date: January 24, 2019Inventor: R. Scott Thies
-
Publication number: 20180291337Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.Type: ApplicationFiled: October 16, 2017Publication date: October 11, 2018Inventors: Melissa K. Carpenter, R. Scott Thies
-
Patent number: 9790466Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.Type: GrantFiled: July 30, 2012Date of Patent: October 17, 2017Assignee: Asterias Biotherapeutics, Inc.Inventors: Melissa K. Carpenter, R. Scott Thies
-
Publication number: 20140134721Abstract: This invention provides a system for obtaining cells of the chondrocyte lineage by differentiating primate pluripotent stem cells. The process involves culturing the cells as a micromass or other aggregate form in a cocktail of differentiation agents that facilitates outgrowth of the desired cell type. Progeny are capable of synthesizing Type II collagen or aggrecan, or other products that are characteristic of the chondrocyte lineage. Chondrocytes and chondrocyte precursor cells obtained according to this disclosure are suitable for use in both research and clinical therapy.Type: ApplicationFiled: August 30, 2013Publication date: May 15, 2014Applicant: Asterias Biotherapeutics, Inc.Inventor: R. Scott Thies
-
Publication number: 20130274215Abstract: The present invention provides methods for the prevention, treatment and/or amelioration of fibrosis or fibrotic conditions. The present invention further provides small molecule inhibitors of Wnt- and TGF-p-mediated ?-catenin signaling to prevent, treat and/or ameliorate fibrosis or fibrotic conditions. Kits comprising small molecule inhibitors of Wnt- and TGF-p-mediated ?-catenin signaling and methods of identifying small molecule inhibitors of Wnt- and TGF-p-mediated ?-catenin signaling are also provided.Type: ApplicationFiled: April 6, 2011Publication date: October 17, 2013Applicant: FATE THERAPEUTICS, INC.Inventors: R. Scott Thies, Francine S. Farouz, David Jenkins
-
Patent number: 8546101Abstract: This invention provides a system for obtaining cells of the chondrocyte lineage by differentiating primate pluripotent stem cells. The process involves culturing the cells as a micromass or other aggregate form in a cocktail of differentiation agents that facilitates outgrowth of the desired cell type. Progeny are capable of synthesizing Type II collagen or aggrecan, or other products that are characteristic of the chondrocyte lineage. Chondrocytes and chondrocyte precursor cells obtained according to this disclosure are suitable for use in both research and clinical therapy.Type: GrantFiled: February 4, 2011Date of Patent: October 1, 2013Assignee: Geron CorporationInventor: R. Scott Thies
-
Publication number: 20120322146Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.Type: ApplicationFiled: July 30, 2012Publication date: December 20, 2012Inventors: Melissa K. Carpenter, R. Scott Thies
-
Patent number: 8252586Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.Type: GrantFiled: June 3, 2009Date of Patent: August 28, 2012Assignee: Geron CorporationInventors: Melissa K. Carpenter, R. Scott Thies
-
Publication number: 20120207744Abstract: The present invention provides compositions and methods of using the compositions to alter the developmental potency of a cell. The present invention provides in vivo and ex vivo cell reprogramming and programming methods suitable for autologous cell therapy and regenerative medicine.Type: ApplicationFiled: March 19, 2010Publication date: August 16, 2012Inventors: John D. Mendlein, Francine S. Farouz, R. Scott Thies, Daniel Shoemaker
-
Publication number: 20120202288Abstract: Provided are improved pharmaceutical compositions that comprise ligands or agonists to prostaglandin EP receptors, and/or cyclic AMP enhancers, and suitable organic solvents that are substantially free of methyl acetate, the compositions being provided for storage and/or use in an endotoxin-free vessel, such as a tube or PE bag. The compositions are suitable for in vitro, ex vivo, and in vivo use, and in particular for ex vivo therapeutic use, such as in hematopoietic stem cell transplants. Also provided are methods of using the compositions in ex vivo therapeutic applications, and methods of preparing the compositions. Kits with instructions on use are also provided.Type: ApplicationFiled: March 18, 2010Publication date: August 9, 2012Applicant: FATE THERAPEUTICS, INC.Inventors: John D. Mendlein, Francine S. Farouz, R. Scott Thies, Daniel Shoemaker
-
Patent number: 8153428Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.Type: GrantFiled: July 10, 2009Date of Patent: April 10, 2012Assignee: Geron CorporationInventors: Melissa K. Carpenter, R. Scott Thies
-
Publication number: 20110129867Abstract: This invention provides a system for obtaining cells of the chondrocyte lineage by differentiating primate pluripotent stem cells. The process involves culturing the cells as a micromass or other aggregate form in a cocktail of differentiation agents that facilitates outgrowth of the desired cell type. Progeny are capable of synthesizing Type II collagen or aggrecan, or other products that are characteristic of the chondrocyte lineage. Chondrocytes and chondrocyte precursor cells obtained according to this disclosure are suitable for use in both research and clinical therapy.Type: ApplicationFiled: February 4, 2011Publication date: June 2, 2011Inventor: R. Scott Thies
-
Patent number: 7906330Abstract: This invention provides a system for obtaining cells of the chondrocyte lineage by differentiating primate pluripotent stem cells. The process involves culturing the cells as a micromass or other aggregate form in a cocktail of differentiation agents that facilitates outgrowth of the desired cell type. Progeny are capable of synthesizing Type II collagen or aggrecan, or other products that are characteristic of the chondrocyte lineage. Chondrocytes and chondrocyte precursor cells obtained according to this disclosure are suitable for use in both research and clinical therapy.Type: GrantFiled: February 1, 2006Date of Patent: March 15, 2011Assignee: Geron CorporationInventor: R. Scott Thies
-
Patent number: 7763463Abstract: This disclosure provides improved methods for obtaining populations of dopaminergic neurons from pluripotent stem cells. The process involves taking a population of neural precursor cells derived from a line of human embryonic stem cells, and culturing the cells in a medium that contains a neurotrophin, either cyclic adenosine monophosphate (cAMP) or a compound that elevates intracellular cAMP levels, and optionally an antioxidant such as ascorbic acid. Cell populations have been obtained that contain a high proportion of cells staining for tyrosine hydroxylase, which is a feature of dopaminergic neurons. The neural progenitors and terminally differentiated neurons of this invention can be generated in large quantities for use in drug screening and the treatment of clinically important neurological disorders, such as Parkinson's disease.Type: GrantFiled: December 10, 2004Date of Patent: July 27, 2010Assignee: Geron CorporationInventors: Melissa K. Carpenter, R. Scott Thies
-
Publication number: 20090305405Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.Type: ApplicationFiled: July 10, 2009Publication date: December 10, 2009Applicant: GERON CORPORATIONInventors: Melissa K. Carpenter, R. Scott Thies
-
Publication number: 20090291495Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.Type: ApplicationFiled: June 3, 2009Publication date: November 26, 2009Applicant: Geron CorporationInventors: Melissa K. Carpenter, R. Scott Thies
-
Patent number: 7560281Abstract: This invention provides a system for efficiently producing differentiated cells from pluripotent cells, such as human embryonic stem cells. Rather than permitting the cells to form embryoid bodies according to established techniques, differentiation is effected directly in monolayer culture on a suitable solid surface. The cells are either plated directly onto a differentiation-promoting surface, or grown initially on the solid surface in the absence of feeder cells and then exchanged into a medium that assists in the differentiation process. The solid surface and the culture medium can be chosen to direct differentiation down a particular pathway, generating a cell population that is remarkably uniform. The methodology is well adapted to bulk production of committed precursor and terminally differentiated cells for use in drug screening or regenerative medicine.Type: GrantFiled: December 10, 2004Date of Patent: July 14, 2009Assignee: Geron CorporationInventors: Melissa K. Carpenter, R. Scott Thies
-
Patent number: 7250294Abstract: This invention provides populations of neural progenitor cells and differentiated neurons, obtained by culturing pluripotent cells in special growth cocktails. The technology can be used to produce progenitors that proliferate through at least ˜40 doublings, while maintaining the ability to differentiate into a variety of different neural phenotypes, including dopaminergic neurons. The neural progenitors and terminally differentiated neurons of this invention can be generated in large quantities for use in drug screening and the treatment of neurological disorders.Type: GrantFiled: May 28, 2002Date of Patent: July 31, 2007Assignee: Geron CorporationInventors: Melissa K. Carpenter, Jerrod J. Denham, Margaret S. Inokuma, R. Scott Thies
-
Patent number: 7091007Abstract: Novel serine/threonine receptor proteins and BMP receptor proteins are disclosed, as well as DNA molecules encoding the BMP receptor proteins and methods of using the receptor proteins. Further disclosed are truncated BMP receptor proteins and molecules which act as ligands to the BMP receptor proteins.Type: GrantFiled: June 23, 2003Date of Patent: August 15, 2006Assignee: Genetics Institute, LLCInventors: John M. Wozney, Anthony J. Celeste, R. Scott Thies, Noboru Yamaji